Latest Breaking News On - Ingeneron inc - Page 1 : comparemela.com

Stromal Vascular Fraction Global Strategic Research Report

Dublin, May 30, 2024 (GLOBE NEWSWIRE) The

United statesIngeneron incObatala sciencesKyocera corporationGe healthcareIntellicell biosciences incStempeutics research pvt ltdGenesis biosystems incJointechlabs incVascular fractionStrategic businessStromal vascular fraction marketStromal vascular fractionAspiration productsWhile chinaMarket value

InGeneron Announces Critical In-Depth Analysis of the Results from a Recently Published 480-Patient Phase III Knee Osteoarthritis Trial

InGeneron Announces Critical In-Depth Analysis of the Results from a Recently Published 480-Patient Phase III Knee Osteoarthritis Trial
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Rheinland pfalzChristoph schmitzMarcus deayalaIngeneron incCorporate developmentJournal nature medicineKnee painCorticosteroid injectionMore questionsChristopher altOsteoarthritis cartilageNature medicineCurrent clinicalStrategy manager

InGeneron Reports Positive Long-Term Results for its Cell Therapy in Partial-Thickness Rotator Cuff Tears

InGeneron Reports Positive Long-Term Results for its Cell Therapy in Partial-Thickness Rotator Cuff Tears
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMarcus deayalaCorporate developmentIngeneron incScientific reportsExecutive chairman eckhard altCurrent clinicalStrategy manager

InGeneron Reports Positive Long-Term Results for its Cell Therapy in Partial-Thickness Rotator Cuff

Randomized controlled trial meets primary endpoint and finds statistically significant durable patient benefit 3.4 years post-treatmentHOUSTON (BUSINESS WIRE) InGeneron, Inc., a clinical-stage biotechnology company, today announced positive clinical trial data demonstrating long-term safety and efficacy of InGener.

United statesIngeneron incScientific reportsExecutive chairman eckhard altCurrent clinical

Stromal Vascular Fraction Global Market to Reach $116 9

Dublin, July 11, 2023 (GLOBE NEWSWIRE) The "Stromal Vascular Fraction: Global Strategic Business Report" report has been added to .

United statesTissue genesis incCellular biomedicines group incGe healthcareIngeneron incGenesis biosystems incCytori therapeutics incVascular fractionGlobal strategic businessStromal vascular fractionAspiration productsWhile chinaBiomedicines groupMarket valueTopics coveredKey competitors percentage market share